BioCryst Pharmaceuticals, Inc.（BCRX）财务数据BCRXBioCryst Pharmaceuticals, Inc.

Evaluating the bottom line, BioCryst Pharmaceuticals, Inc. maintains a gross margin of 98.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 45.12%, while the net margin is 35.92%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCRX converts its operational activities into shareholder value.

In the context of the broader market, BCRX competes directly with industry leaders such as VERA and ADRX. With a market capitalization of $2.05B, it holds a leading position in the sector. When comparing efficiency, BCRX's gross margin of 98.24% stands against VERA's N/A and ADRX's N/A. Such benchmarking helps identify whether BioCryst Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

BioCryst's revenue from Orladeyo is expected to be between $625 million and $645 million for 2026, with a gross margin of 98.24% in Q2 2026, indicating strong profitability despite recent challenges.